136 related articles for article (PubMed ID: 27614350)
1. Assessment of cancer and virus antigens for cross-reactivity in human tissues.
Jaravine V; Raffegerst S; Schendel DJ; Frishman D
Bioinformatics; 2017 Jan; 33(1):104-111. PubMed ID: 27614350
[TBL] [Abstract][Full Text] [Related]
2. Expitope: a web server for epitope expression.
Haase K; Raffegerst S; Schendel DJ; Frishman D
Bioinformatics; 2015 Jun; 31(11):1854-6. PubMed ID: 25644270
[TBL] [Abstract][Full Text] [Related]
3. Expitope 2.0: a tool to assess immunotherapeutic antigens for their potential cross-reactivity against naturally expressed proteins in human tissues.
Jaravine V; Mösch A; Raffegerst S; Schendel DJ; Frishman D
BMC Cancer; 2017 Dec; 17(1):892. PubMed ID: 29282079
[TBL] [Abstract][Full Text] [Related]
4. T-cell-receptor-like antibodies - generation, function and applications.
Dahan R; Reiter Y
Expert Rev Mol Med; 2012 Feb; 14():e6. PubMed ID: 22361332
[TBL] [Abstract][Full Text] [Related]
5. Epitope distribution in ordered and disordered protein regions - part A. T-cell epitope frequency, affinity and hydropathy.
Mitić NS; Pavlović MD; Jandrlić DR
J Immunol Methods; 2014 Apr; 406():83-103. PubMed ID: 24614036
[TBL] [Abstract][Full Text] [Related]
6. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
[TBL] [Abstract][Full Text] [Related]
8. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
Stone JD; Harris DT; Kranz DM
Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219
[TBL] [Abstract][Full Text] [Related]
9. Automated benchmarking of peptide-MHC class I binding predictions.
Trolle T; Metushi IG; Greenbaum JA; Kim Y; Sidney J; Lund O; Sette A; Peters B; Nielsen M
Bioinformatics; 2015 Jul; 31(13):2174-81. PubMed ID: 25717196
[TBL] [Abstract][Full Text] [Related]
10. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions.
Larsen MV; Lundegaard C; Lamberth K; Buus S; Brunak S; Lund O; Nielsen M
Eur J Immunol; 2005 Aug; 35(8):2295-303. PubMed ID: 15997466
[TBL] [Abstract][Full Text] [Related]
11. The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy.
Singh-Jasuja H; Emmerich NP; Rammensee HG
Cancer Immunol Immunother; 2004 Mar; 53(3):187-95. PubMed ID: 14758508
[TBL] [Abstract][Full Text] [Related]
12. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.
Fluckiger A; Daillère R; Sassi M; Sixt BS; Liu P; Loos F; Richard C; Rabu C; Alou MT; Goubet AG; Lemaitre F; Ferrere G; Derosa L; Duong CPM; Messaoudene M; Gagné A; Joubert P; De Sordi L; Debarbieux L; Simon S; Scarlata CM; Ayyoub M; Palermo B; Facciolo F; Boidot R; Wheeler R; Boneca IG; Sztupinszki Z; Papp K; Csabai I; Pasolli E; Segata N; Lopez-Otin C; Szallasi Z; Andre F; Iebba V; Quiniou V; Klatzmann D; Boukhalil J; Khelaifia S; Raoult D; Albiges L; Escudier B; Eggermont A; Mami-Chouaib F; Nistico P; Ghiringhelli F; Routy B; Labarrière N; Cattoir V; Kroemer G; Zitvogel L
Science; 2020 Aug; 369(6506):936-942. PubMed ID: 32820119
[TBL] [Abstract][Full Text] [Related]
13. Characterizing neoantigens for personalized cancer immunotherapy.
Capietto AH; Jhunjhunwala S; Delamarre L
Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
[TBL] [Abstract][Full Text] [Related]
14. Prediction of cancer neoepitopes needs new rules.
Brennick CA; George MM; Srivastava PK; Karandikar SH
Semin Immunol; 2020 Feb; 47():101387. PubMed ID: 31952902
[TBL] [Abstract][Full Text] [Related]
15. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
[TBL] [Abstract][Full Text] [Related]
16. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes.
Tourdot S; Scardino A; Saloustrou E; Gross DA; Pascolo S; Cordopatis P; Lemonnier FA; Kosmatopoulos K
Eur J Immunol; 2000 Dec; 30(12):3411-21. PubMed ID: 11093159
[TBL] [Abstract][Full Text] [Related]
17. Properties of MHC class I presented peptides that enhance immunogenicity.
Calis JJ; Maybeno M; Greenbaum JA; Weiskopf D; De Silva AD; Sette A; Keşmir C; Peters B
PLoS Comput Biol; 2013 Oct; 9(10):e1003266. PubMed ID: 24204222
[TBL] [Abstract][Full Text] [Related]
18. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.
Tan MP; Gerry AB; Brewer JE; Melchiori L; Bridgeman JS; Bennett AD; Pumphrey NJ; Jakobsen BK; Price DA; Ladell K; Sewell AK
Clin Exp Immunol; 2015 May; 180(2):255-70. PubMed ID: 25496365
[TBL] [Abstract][Full Text] [Related]
19. Thermostability profiling of MHC-bound peptides: a new dimension in immunopeptidomics and aid for immunotherapy design.
Jappe EC; Garde C; Ramarathinam SH; Passantino E; Illing PT; Mifsud NA; Trolle T; Kringelum JV; Croft NP; Purcell AW
Nat Commun; 2020 Dec; 11(1):6305. PubMed ID: 33298915
[TBL] [Abstract][Full Text] [Related]
20. Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation.
He X; Tsang TC; Luo P; Zhang T; Harris DT
Cancer Gene Ther; 2003 Sep; 10(9):669-77. PubMed ID: 12944986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
